Bristol-Myers Squibb wins label extension for Opdivo to include new dosing schedule

Bristol-Myers Squibb (NYSE: BMS), the US-based Opdivo (nivolumab) development partner of Japan’s Ono Pharmaceuticals (TYO: 4528), has won an extension to the US label for the landmark immuno-oncology therapy.

The US Food and Drug Administration granted an addition to the label, describing a new dosing schedule to include 480mg infused every four weeks (Q4W) for a majority of approved indications.

Opdivo also was approved for a shorter 30-minute infusion across all approved indications.